Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Johnson Chemical Pharmaceutical Works Co Buyback Yield % Chart
Johnson Chemical Pharmaceutical Works Co Annual Data
ROCO:4747 vs ZTS, UTHR: Buyback Yield % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Johnson Chemical Pharmaceutical Works Co's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Johnson Chemical Pharmaceutical Works Co Buyback Yield % vs Drug Manufacturers Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Johnson Chemical Pharmaceutical Works Co (ROCO:4747) has a Buyback Yield % of 0.00 as of Jul. 25, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Johnson Chemical Pharmaceutical Works Co and its competitors. According to the industry distribution chart, Johnson Chemical Pharmaceutical Works Co ranks #999999 out of 290 companies in the Drug Manufacturers industry.
Is Johnson Chemical Pharmaceutical Works Co's Buyback Yield % too high?
Johnson Chemical Pharmaceutical Works Co's current Buyback Yield % is 0.00. Based on the distribution chart, Johnson Chemical Pharmaceutical Works Co ranks #999999 out of 290 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Johnson Chemical Pharmaceutical Works Co has a GF Score™ of 77/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Johnson Chemical Pharmaceutical Works Co's Buyback Yield % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Johnson Chemical Pharmaceutical Works Co ranks #999999 out of 290 companies for Buyback Yield %. This places Johnson Chemical Pharmaceutical Works Co in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Drug Manufacturers company?
A good Buyback Yield % depends on the Drug Manufacturers industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Johnson Chemical Pharmaceutical Works Co and its competitors. Johnson Chemical Pharmaceutical Works Co's current Buyback Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Johnson Chemical Pharmaceutical Works Co stock overvalued right now?
Based on GuruFocus' analysis, Johnson Chemical Pharmaceutical Works Co (ROCO:4747) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$60.10, compared to a current price of NT$49.80 — trading 17.1% below its estimated fair value. The current Buyback Yield % is 0.00. Johnson Chemical Pharmaceutical Works Co's overall GF Score™ is 77/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Johnson Chemical Pharmaceutical Works Co (ROCO:4747), the current Buyback Yield % is 0.00 as of Jul. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Johnson Chemical Pharmaceutical Works Co (ROCO:4747) Overvalued in 2026?
Based on GuruFocus' analysis, Johnson Chemical Pharmaceutical Works Co stock appears to be undervalued.
The current stock price of NT$49.80 is trading 17.1% below its estimated GF Value™ of NT$60.10.
GuruFocus considers Johnson Chemical Pharmaceutical Works Co to be Modestly Undervalued.
Key valuation signals for ROCO:4747:
Buyback Yield %: 0.00
GF Value™: NT$60.10 vs. price of NT$49.80 (17.1% below fair value)
No single metric tells the full story. See the ROCO:4747 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Johnson Chemical Pharmaceutical Works Co Business Description
Johnson Chemical Pharmaceutical Works Co is engaged in the manufacturing of pharmaceutical ingredients, importing and selling pharmaceutical materials and products. It manufactures drugs in a variety of forms, including solid dosage forms, capsules (soft/hard), tablets (sugar/film-coated), powder and granule, as well as nasal sprays. It offers products in therapeutic areas including the central nervous system, respiratory, cardiovascular, gastrointestinal, and endocrine system, vitamins, anti-inflammatory, cough and cold, and pain relievers. Its revenue mainly comes from medical product sales.
77GF Score
Get the complete analysis for ROCO:4747
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4747 has been successfully added to your 
